U mean y not what deaar!!
The answer to this question is b
Genetic variation can<span> be </span>caused<span> by </span>mutation<span> (which </span>can<span> create entirely new alleles in a population), random mating, random fertilization, and recombination between homologous chromosomes during meiosis (which reshuffles alleles within an organism's offspring).</span>
The ecosystem is defined as the stable interaction of biotic and abiotic factors in the surroundings. The intertidal is a zone of ecosystem found between land and water.
<h3>What is the Intertidal Zone of Ecosystem?</h3>
- The intertidal zone is defined as the point or site where the ocean meets the land between high and low tides. The zone can be found at any point where the land meets the ocean.
- The ecosystem found in the intertidal zones are estuaries, tide pools, and salt marshes.
Thus, the intertidal zone supports the ecosystem of marshes, tidal pools, and estuaries.
Learn more about the <u>ecosystem </u>here:
brainly.com/question/1673533
Answer:
Thanks for you question. Your hypothesis suggests a linear relationship between serum Cholesterol levels and MI. This hypothesis seems to ignore the difference in the prevalence and effectiveness of LDL receptors in the FH patient.
FH patients who have inherited the mutation from both parents have very few LDL receptors in their blood and therefore almost no ability to pass the unused Cholesterol through the liver. FH patients who are heterozygous will have more LDL receptors although both will find Cholesterol removal problematic without the addition of a PCSK9 inhibitor.
In short, your hypothesis need to account for other factors that are in play.
Explanation:
Consider my case. I am a 64 year old male who has Heterozygous Familial Hypercholesterolemia. Before treatment at age 12 my Total cholesterol was 510 mg/dl. My genetic testing shows two mutations to the LDL Receptor gene with only one mutation being pathogenic. My first heart attack was at 47 and first stroke at 62. My current LDL is too low to detect with the use of a PCSK9 inhibitor (Repatha®).
